Literature DB >> 18273583

[Angiosarcoma].

T Vogt1.   

Abstract

Angiosarcomas are rare tumors accounting for 1-2% of all soft tissue sarcomas. Nonetheless a dermatologist needs to be knowledgeable about this tumor because the prognosis is particularly poor. Angiosarcoma favors superficial soft tissues and skin (60%) with a clear predilection for the head and neck region. The average age of the patients presenting with cutaneous angiosarcomas is around 70 years with a peak incidence in the 8th decade. However, some subtypes may occur in children and adolescents. Secondary angiosarcoma after tissue-conserving radiation therapy for carcinoma of the breast represents an increasing problem, both the differentiation between atypical vascular lesions and true aggressive angiosarcoma and the therapy are challenging. The prognosis for angiosarcoma patients is gloomy despite all therapeutic efforts. Only early therapy seems to influence the outcome at all. There are some established guidelines for the primary and palliative therapy. Interesting new options of biomodulatory and molecularly targeted therapy can be envisioned.

Entities:  

Mesh:

Year:  2008        PMID: 18273583     DOI: 10.1007/s00105-008-1486-2

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   1.198


  26 in total

1.  The urokinase plasminogen activator system in angiosarcoma, Kaposi's sarcoma, granuloma pyogenicum, and angioma: an immunohistochemical study.

Authors:  M Thewes; E Elsner; D Wessner; R Engst; J Ring
Journal:  Int J Dermatol       Date:  2000-03       Impact factor: 2.736

2.  Expression of FKBP12 in benign and malignant vascular endothelium: an immunohistochemical study on conventional sections and tissue microarrays.

Authors:  John P T Higgins; Kelli Montgomery; Lingli Wang; Elizabeth Domanay; Roger A Warnke; James D Brooks; Matt van de Rijn
Journal:  Am J Surg Pathol       Date:  2003-01       Impact factor: 6.394

Review 3.  Cutaneous angiosarcoma.

Authors:  William M Mendenhall; Charles M Mendenhall; John W Werning; John D Reith; Nancy P Mendenhall
Journal:  Am J Clin Oncol       Date:  2006-10       Impact factor: 2.339

4.  A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy.

Authors:  Matthew G Fury; Cristina R Antonescu; Kimberly J Van Zee; Murray F Brennan; Robert G Maki
Journal:  Cancer J       Date:  2005 May-Jun       Impact factor: 3.360

5.  Vascular proliferations of the skin after radiation therapy for breast cancer: clinicopathologic analysis of a series in favor of a benign process: a study from the French Sarcoma Group.

Authors:  Carole Gengler; Jean-Michel Coindre; Agnés Leroux; Martine Trassard; Dominique Ranchère-Vince; Isabelle Valo; Jean-Jacques Michels; Louis Guillou
Journal:  Cancer       Date:  2007-04-15       Impact factor: 6.860

6.  Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma.

Authors:  Keith M Skubitz; Philip A Haddad
Journal:  Cancer       Date:  2005-07-15       Impact factor: 6.860

7.  Angiostatin receptor annexin II in vascular tumors including angiosarcoma.

Authors:  Sajjad P Syed; Anne-Marie Martin; Helen M Haupt; Carmen P Arenas-Elliot; John J Brooks
Journal:  Hum Pathol       Date:  2007-01-19       Impact factor: 3.466

8.  Treatment of scalp angiosarcoma by controlled perfusion of A. carotis externa with pegylated liposomal doxorubicin and intralesional application of pegylated interferon alfa.

Authors:  Anne B Bong; Bernd Bonnekoh; Michael Peter Schön; Harald Gollnick
Journal:  J Am Acad Dermatol       Date:  2005-02       Impact factor: 11.527

9.  Hemangiosarcomas, medulloblastomas, and other tumors in Ink4c/p53-null mice.

Authors:  Frederique Zindy; Lisa M Nilsson; Luc Nguyen; Cecile Meunier; Richard J Smeyne; Jerold E Rehg; Charles Eberhart; Charles J Sherr; Martine F Roussel
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

10.  Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors.

Authors:  Thomas Vogt; Christian Hafner; Klaus Bross; Frauke Bataille; Karl-Walter Jauch; Anna Berand; Michael Landthaler; Reinhard Andreesen; Albrecht Reichle
Journal:  Cancer       Date:  2003-11-15       Impact factor: 6.860

View more
  2 in total

1.  Multidisciplinary approach to breast angiosarcoma in an elderly patient: Repeated local relapses and significant objective responses.

Authors:  Carmela Mocerino; Giuseppe Iannaci; Patrizia Sapere; Rossella Luise; Silvestro Canonico; Antonio Gambardella
Journal:  Int J Immunopathol Pharmacol       Date:  2016-02-12       Impact factor: 3.219

2.  Small intestine bleeding due to multifocal angiosarcoma.

Authors:  Luisa Zacarias Föhrding; Arne Macher; Stefan Braunstein; Wolfram Trudo Knoefel; Stefan Andreas Topp
Journal:  World J Gastroenterol       Date:  2012-11-28       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.